Dermatology News

Pediatric patients who were hospitalized with COVID-19 often experienced mucocutaneous symptoms, according to a study.

ACP, citing previous data that indicate at least 30% of outpatient antibiotic prescriptions in the U.S. were “unnecessary” and “often continued for too long,” issued best practices for appropriate antibiotic use in several bacterial infections.

A daily 30 mg dose of upadacitinib — but not the 15 mg dose — is superior to adalimumab at improving the signs and symptoms of psoriatic arthritis among patients with inadequate response to non-biologic disease-modifying antirheumatic drugs.

Patients with inflammatory rheumatic disease, but especially those with autoimmune conditions, as well as those treated with rituximab, may be at greater risk for severe COVID-19 pneumonia than the general population, according to data.

Alopecia, a condition with various subtypes and etiologies, is a “common and distressing clinical complaint in the primary care setting,” researchers wrote in Frontiers in Medicine.

Both 100 mg and 200 mg doses of once-daily abrocitinib improved signs and symptoms in patients with moderate to severe atopic dermatitis, according to a study.

Anxiety and depression symptoms reduce the likelihood of achieving sustained minimal disease activity in psoriatic arthritis, according to data published in Arthritis Care & Research.

About half of the first-year positions that were offered in the 2021 Main Residency Match were in primary care, family medicine, internal medicine and pediatrics, and most of these positions have been filled, according to the National Resident Matching Program.

This episode details how psoriatic arthritis and the spondyloarthropathies came to be recognized as a distinct clinical entity after decades of nerdy arguing.

Joel M. Gelfand, MD, MSCE, professor of dermatology and epidemiology at the University of Pennsylvania, discusses an upcoming program from the National Heart, Lung, and Blood Institute.